Skip to main content

Eureka Genomics Reels in $3.7M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eureka Genomics has netted $3.7 million in financing through a private round that included individuals and undisclosed angel investors.

The Hercules, Calif.-based company said today that it plans to use the funding to advance its studies of novel microorganisms linked to specific cancers and other diseases, and to boost sales and marketing for its high-throughput sequencing data and bioinformatics service businesses.

"This funding will support the advancement of our lead programs in colorectal cancer, lymphoma, and cardiovascular disease," Eureka Genomics COO and Co-founder Didier Perez said in a statement. "Our advanced next-generation sequencing and bioinformatics capabilities have already resulted in the discovery of unique microbial associations with disease in animals and plants, and we are working to extend our discoveries to humans."

He added that the firm intends to add new partners over the coming year, which would include corporate collaborators for the co-development and commercialization of vaccines and diagnostics based on Eureka's discoveries.

Names of the investors in this round of funding were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.